Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/β-catenin signaling inhibitor.
スポンサーリンク
概要
- 論文の詳細を見る
We investigated the effect of a novel Wnt/β-catenin signaling inhibitor, AV65 on imatinib mesylate (IM)-sensitive and -resistant human chronic myeloid leukemia (CML) cells in vitro. AV65 inhibited the proliferation of various CML cell lines including T315I mutation-harboring cells. AV65 reduced the expression of β-catenin in CML cells, resulting in the induction of apoptosis. Moreover, AV65 inhibited the proliferation of hypoxia-adapted primitive CML cells that overexpress β-catenin. The combination of AV65 with IM had a synergistic inhibitory effect on the proliferation of CML cells. These findings suggest that AV65 could be a novel therapeutic agent for the treatment of CML.
- 2011-12-15
論文 | ランダム
- 50) 右室流出路閉塞をきたした心臓原発性平滑筋肉腫の1例
- 89) Cryoablationにて治癒した脚間及び脚枝間リエントリーの1例
- P579 Kent束の伝導途絶部位
- 45)冠動脈病変を合併した複数コンポーネントKent束WPW症候群の一例
- 41)待機的に僧帽弁形成術, 冠動脈バイパス術を施行した心筋梗塞後乳頭筋断裂の1例